ESC-HFA 2023: Late-Breaking Science Video Collection

Published: 23 May 2023

  • Views:

    Views Icon 3160

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Get the most out of the new data from, Late-breaker host, Dr Harriette Van Spall and Dr James Januzzi wrap up of the most impactful trials and studies presented at Heart Failure 2023.

Delve into in-depth and critical discussions with Dr Van Spall in our thought-provoking Late-breaker Discussion series.

For concise and practical take-home messages for practice and cardiovascular research watch our 5-minute Expert Interviews conducted with investigators.

Watch our Behind the Heart Series to hear more from the personal perspectives of the investigators behind the top trials of HFA 2023. 

More from this programme

Part 1

Late-breaker Discussions with Dr Van Spall

4 sessions
Hospital to Home in HF: Insights from ACT-HF, PROMPT-AHF & STRONG-HF Kidney Watch now
The PARAGLIDE-HF Trial Watch now
HFA 2023 Late-breaking Science Highlights With Dr Van Spall & Dr Januzzi Watch now
TRACER-HF: Trientine-HCL for Treatment of Heart Failure and Reduced Ejection Fraction Watch now

Part 2

Expert Interviews

10 sessions
MONITOR-HF: Improving QoL& Reducing HF Hospitalisations with PAP Monitoring Watch now
REDWOOD-HCM-Cohort 4: Aficamten in Non-obstructive Hypertrophic Cardiomyopathy Watch now
APOLLO-B: Patisiran Treatment for Cardiac Amyloidosis Watch now
DAPA-HF and DELIVER: KCCQ in Patients with Varying Ejection Fraction Watch now
DAPA MODA: Dapaglifozin & Cardiac Remodelling in Chronic HF Watch now
NUDGE-FLU: Increasing Influenza Vaccination in HF Patients Watch now
DAPA-RESIST: Dapagliflozin Vs Metolazone in Diuretic-Resistant HF Watch now
TRANSFORM-HF: Torsemide Vs Furosemide on Quality of Life in Heart Failure Watch now
Diagnosis in Heart Failure in Women Watch now
Dapagliflozin and Peripheral Arterial Disease in Heart Failure Watch now

About the episode

Dr Ankeet Bhatt (Kaiser Permanante San Francisco Medical Center, US) joins us to discuss a study that looked into Kansas City Cardiomyopathy Questionnaire (KCCQ) scores in patients with varying ejection fractions, that were enrolled in the DELIVER and DAPA-HF trials.

This study used pooled, patient-level data from the DAPA-HF and DELIVER studies, aiming to examine the impact effects of dapagliflozin health status across the full spectrum of LVEF. 

Results suggest that dapagliflozin improved health status as measured by KCCQ scores at both 4 and 8 months post-randomization. These improvements were consistently observed across the full spectrum of LVEF. 

Interview Questions: 

  1. What was the reasoning behind comparing the DAPA-HF and DELIVER Trials?
  2. What is the current landscape of research into dapagliflozin in 2023?
  3. What was the study design and patient cohort?
  4. What are the key findings?
  5. How does this analysis shed new light on the findings of both DAPA and DELIVER?
  6. How should the results of this study be applied to clinical practice?
  7. What further study is needed?

Faculty Biographies

Ankeet Bhatt

View full profile

Comments

You must be to comment. If you are not registered, you can register here.